Image Source: PixabayThe 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 3.4%, on average, last week and below is how each constituent stock performed, in descending order, and YTD, plus any recent news, commentary, and/or analysis on each company:
- is primarily focused on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
- Latest News, Commentary and/or Analysis:
- MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
- is focused on the use of ketamine, DMT and ibogaine. Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
- Latest News, Commentary and/or Analysis:
- atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
- is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
- Latest News, Commentary and/or Analysis:
- GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
- is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Latest News, Commentary and/or Analysis:
- Compass Pathways Announces Q4 2023 Financial Results and Business Highlights
- is researching and developing therapies and products with the world’s largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
- Latest News, Commentary and/or Analysis: None
Summary
The munKNEE Psychedelic compound-Based Drug Stocks Index went UP 3.4% last week and is now UP 44.1% YTD.More By This Author:Our 7 Largest Cannabis MSO Stocks Dropped 7.1% Last Week
Cannabis Company Green Thumb Has Bounced Back From A Rocky Q4
Q4 Results Of Cannabis Company Verano Holdings Were Down Across The Board
